Sciomics GmbH Information

Sciomics has extensive expertise in the area of biomarker discovery, in vitro as well as in vivo model system characterisation and disease mechanism profiling using its high-content protein and post-translational modification profiling platform in an analysis service setting and for internal research. More than 1,000 proteins are currently analysed by the proprietary fully immuno-based scioDiscover antibody array platform in a single assay with minimal sample requirements. Information on the protein abundance can be combined with the phosphorylation, ubiquitination or methylation status of these proteins. The high-content and high-throughput platform guarantees robust and reproducible results which - due to its immuno-based nature - can easily be translated into validation as well as clinical assays. The platform's main applications are the discovery of protein biomarkers, screening and verification of new drug targets, pathway activity profiling as well as drug mode-of-action analysis.